BioGenex RT-PCR Kit detects all Covid variants in half the time

BioGenex RT-PCR Kit detects all Covid variants in half the time

By: IPP Bureau

Last updated : January 13, 2022 1:40 pm



This test analyses samples in VTM directly without the need for RNA extraction step


BioGenex Life Sciences has developed a RT-PCR kit for Covid-19 diagnosis, which detects Covid-19 caused by SARS COV 2 variants including Omicron plus other variants, the company stated in a release.

The company in the release said that the NIB, Noida, an ICMR designated lab, examined the performance of this kit and found that it performed with 100% accuracy which means no false negatives or positives, which will significantly control the pandemic through accurate diagnosis. The kit detects Omicron variant in half the time than standard RT-PCR test.


The Triplex Covid-19 RT-PCR Direct is a real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 directly from the upper respiratory swab, nasopharyngeal or oropharyngeal swabs, collected in preservative media, (VTM/UTM), pH 7.2-7.4 to provide the molecular diagnostic basis for infected patients.

This test analyses samples in VTM directly without the need for RNA extraction step. It helps scientists for rapid tracking of disease prevalence and aid in treatment insight for healthcare systems in making appropriate measures to combat Covid-19.

“There are many challenges associated with ramping up testing capacity, due to supply chain delays and shortage of extraction reagents, this situation call-up for alternative protocols to ensure the continuity of testing in laboratories. Due to increased demand for SARS-CoV-2 variants screenings, an alternative protocol with similar sensitivity is required, “said Dr. Krishan Kalra, CEO BioGenex.

He further added, “Sustained surveillance is essential for public health. Our latest tests reduce the cost of testing and turnaround time for the result. As we learn from the pandemic, we are partnering with concerned organizations to understand and strengthen our diagnostic portfolio to develop-deliver reliable and sustainable diagnostic solutions in the future.”

 

BioGenex Life Sciences NIB ICMR Dr Krishan Kalra

First Published : January 13, 2022 12:00 am